CK2 Activity Mediates the Aggressive Molecular Signature of Glioblastoma Multiforme by Inducing Nerve/Glial Antigen (NG)2 Expression

Nerve/glial antigen (NG)2 expression crucially determines the aggressiveness of glioblastoma multiforme (GBM). Recent evidence suggests that protein kinase CK2 regulates NG2 expression. Therefore, we investigated in the present study whether CK2 inhibition suppresses proliferation and migration of N...

Full description

Bibliographic Details
Main Authors: Beate M. Schmitt, Anne S. Boewe, Claudia Götz, Stephan E. Philipp, Steffi Urbschat, Joachim Oertel, Michael D. Menger, Matthias W. Laschke, Emmanuel Ampofo
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Cancers
Subjects:
Online Access:https://www.mdpi.com/2072-6694/13/7/1678
_version_ 1797539013879398400
author Beate M. Schmitt
Anne S. Boewe
Claudia Götz
Stephan E. Philipp
Steffi Urbschat
Joachim Oertel
Michael D. Menger
Matthias W. Laschke
Emmanuel Ampofo
author_facet Beate M. Schmitt
Anne S. Boewe
Claudia Götz
Stephan E. Philipp
Steffi Urbschat
Joachim Oertel
Michael D. Menger
Matthias W. Laschke
Emmanuel Ampofo
author_sort Beate M. Schmitt
collection DOAJ
description Nerve/glial antigen (NG)2 expression crucially determines the aggressiveness of glioblastoma multiforme (GBM). Recent evidence suggests that protein kinase CK2 regulates NG2 expression. Therefore, we investigated in the present study whether CK2 inhibition suppresses proliferation and migration of NG2-positive GBM cells. For this purpose, CK2 activity was suppressed in the NG2-positive cell lines A1207 and U87 by the pharmacological inhibitor CX-4945 and CRISPR/Cas9-mediated knockout of CK2α. As shown by quantitative real-time PCR, luciferase-reporter assays, flow cytometry and western blot, this significantly reduced NG2 gene and protein expression when compared to vehicle-treated and wild type controls. In addition, CK2 inhibition markedly reduced NG2-dependent A1207 and U87 cell proliferation and migration. The Cancer Genome Atlas (TCGA)-based data further revealed not only a high expression of both NG2 and CK2 in GBM but also a positive correlation between the mRNA expression of the two proteins. Finally, we verified a decreased NG2 expression after CX-4945 treatment in patient-derived GBM cells. These findings indicate that the inhibition of CK2 represents a promising approach to suppress the aggressive molecular signature of NG2-positive GBM cells. Therefore, CX-4945 may be a suitable drug for the future treatment of NG2-positive GBM.
first_indexed 2024-03-10T12:39:22Z
format Article
id doaj.art-26bea17c99cf4ee1bf7bc9f00cb1bfee
institution Directory Open Access Journal
issn 2072-6694
language English
last_indexed 2024-03-10T12:39:22Z
publishDate 2021-04-01
publisher MDPI AG
record_format Article
series Cancers
spelling doaj.art-26bea17c99cf4ee1bf7bc9f00cb1bfee2023-11-21T13:58:46ZengMDPI AGCancers2072-66942021-04-01137167810.3390/cancers13071678CK2 Activity Mediates the Aggressive Molecular Signature of Glioblastoma Multiforme by Inducing Nerve/Glial Antigen (NG)2 ExpressionBeate M. Schmitt0Anne S. Boewe1Claudia Götz2Stephan E. Philipp3Steffi Urbschat4Joachim Oertel5Michael D. Menger6Matthias W. Laschke7Emmanuel Ampofo8Institute for Clinical & Experimental Surgery, Saarland University, 66421 Homburg, GermanyInstitute for Clinical & Experimental Surgery, Saarland University, 66421 Homburg, GermanyMedical Biochemistry and Molecular Biology, Saarland University, 66421 Homburg, GermanyExperimental and Clinical Pharmacology and Toxicology, Center for Molecular Signaling (PZMS), Saarland University, 66421 Homburg, GermanyDepartment of Neurosurgery, Faculty of Medicine, Saarland University, 66421 Homburg, GermanyDepartment of Neurosurgery, Faculty of Medicine, Saarland University, 66421 Homburg, GermanyInstitute for Clinical & Experimental Surgery, Saarland University, 66421 Homburg, GermanyInstitute for Clinical & Experimental Surgery, Saarland University, 66421 Homburg, GermanyInstitute for Clinical & Experimental Surgery, Saarland University, 66421 Homburg, GermanyNerve/glial antigen (NG)2 expression crucially determines the aggressiveness of glioblastoma multiforme (GBM). Recent evidence suggests that protein kinase CK2 regulates NG2 expression. Therefore, we investigated in the present study whether CK2 inhibition suppresses proliferation and migration of NG2-positive GBM cells. For this purpose, CK2 activity was suppressed in the NG2-positive cell lines A1207 and U87 by the pharmacological inhibitor CX-4945 and CRISPR/Cas9-mediated knockout of CK2α. As shown by quantitative real-time PCR, luciferase-reporter assays, flow cytometry and western blot, this significantly reduced NG2 gene and protein expression when compared to vehicle-treated and wild type controls. In addition, CK2 inhibition markedly reduced NG2-dependent A1207 and U87 cell proliferation and migration. The Cancer Genome Atlas (TCGA)-based data further revealed not only a high expression of both NG2 and CK2 in GBM but also a positive correlation between the mRNA expression of the two proteins. Finally, we verified a decreased NG2 expression after CX-4945 treatment in patient-derived GBM cells. These findings indicate that the inhibition of CK2 represents a promising approach to suppress the aggressive molecular signature of NG2-positive GBM cells. Therefore, CX-4945 may be a suitable drug for the future treatment of NG2-positive GBM.https://www.mdpi.com/2072-6694/13/7/1678glioblastoma multiformeGBMnerve/glial antigen 2NG2CK2CX-4945
spellingShingle Beate M. Schmitt
Anne S. Boewe
Claudia Götz
Stephan E. Philipp
Steffi Urbschat
Joachim Oertel
Michael D. Menger
Matthias W. Laschke
Emmanuel Ampofo
CK2 Activity Mediates the Aggressive Molecular Signature of Glioblastoma Multiforme by Inducing Nerve/Glial Antigen (NG)2 Expression
Cancers
glioblastoma multiforme
GBM
nerve/glial antigen 2
NG2
CK2
CX-4945
title CK2 Activity Mediates the Aggressive Molecular Signature of Glioblastoma Multiforme by Inducing Nerve/Glial Antigen (NG)2 Expression
title_full CK2 Activity Mediates the Aggressive Molecular Signature of Glioblastoma Multiforme by Inducing Nerve/Glial Antigen (NG)2 Expression
title_fullStr CK2 Activity Mediates the Aggressive Molecular Signature of Glioblastoma Multiforme by Inducing Nerve/Glial Antigen (NG)2 Expression
title_full_unstemmed CK2 Activity Mediates the Aggressive Molecular Signature of Glioblastoma Multiforme by Inducing Nerve/Glial Antigen (NG)2 Expression
title_short CK2 Activity Mediates the Aggressive Molecular Signature of Glioblastoma Multiforme by Inducing Nerve/Glial Antigen (NG)2 Expression
title_sort ck2 activity mediates the aggressive molecular signature of glioblastoma multiforme by inducing nerve glial antigen ng 2 expression
topic glioblastoma multiforme
GBM
nerve/glial antigen 2
NG2
CK2
CX-4945
url https://www.mdpi.com/2072-6694/13/7/1678
work_keys_str_mv AT beatemschmitt ck2activitymediatestheaggressivemolecularsignatureofglioblastomamultiformebyinducingnerveglialantigenng2expression
AT annesboewe ck2activitymediatestheaggressivemolecularsignatureofglioblastomamultiformebyinducingnerveglialantigenng2expression
AT claudiagotz ck2activitymediatestheaggressivemolecularsignatureofglioblastomamultiformebyinducingnerveglialantigenng2expression
AT stephanephilipp ck2activitymediatestheaggressivemolecularsignatureofglioblastomamultiformebyinducingnerveglialantigenng2expression
AT steffiurbschat ck2activitymediatestheaggressivemolecularsignatureofglioblastomamultiformebyinducingnerveglialantigenng2expression
AT joachimoertel ck2activitymediatestheaggressivemolecularsignatureofglioblastomamultiformebyinducingnerveglialantigenng2expression
AT michaeldmenger ck2activitymediatestheaggressivemolecularsignatureofglioblastomamultiformebyinducingnerveglialantigenng2expression
AT matthiaswlaschke ck2activitymediatestheaggressivemolecularsignatureofglioblastomamultiformebyinducingnerveglialantigenng2expression
AT emmanuelampofo ck2activitymediatestheaggressivemolecularsignatureofglioblastomamultiformebyinducingnerveglialantigenng2expression